Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...
Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that results from a Phase 2 clinical study (AROAAT-2002) of investigational fazirsiran (TAK-999/ARO-AAT)...
Takeda ( TSE:4502/NYSE:TAK ) today announced that it has signed a 15-year lease with BioMed Realty for approximately 600,000 square feet of research and development (R&D) and office space to be built...
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Improving your investing process tends to have high returns.
Takeda ( TSE:4502/NYSE:TAK ) today announced that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks...
/CNW/ - Takeda Canada Inc. ("Takeda Canada"), a values-based, R&D-driven biopharmaceutical leader, committed to discovering and delivering life-transforming...
Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of...
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda ( TSE:4502/NYSE:TAK ) announced to transfer the marketing authorization in...
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1, 2022...